Since the merger was announced, IDPH has dropped more than 10 points. The market does not want the merger. The combined company will not be possible to manage, with headquarters divided between East and West coasts. The merger is a CATASTROPHE. VOTE NO.
bgen has antegren which clinical trials are rumored to be better than everything on the market, including avonex. it can be a 2.5-3 billion dollar drug, combined with rituxan, the new company can be a 5-6 billion dollar and what would that do to the share price? only time can tell. however, between now and until the offical release of the antegren trials, idph may languish, but it will double on positive news about antegren. news about antegren for ms is expected in 2h04
I personally consider BGEN to be a poorly run company. To make matters worse, they are the one who will get a controlling interest in management. Therefore, I voted NO against the merger. I realize that my vote has little meaning but it was symbolic.
I have a large holding in Idec and now I'm unsure what to do over the next 24 months. I figured (before the merger) Idec had a good chance of growing by a factor of 4 over the next 3 years. Now, I guess maybe 1.5 to 2.
Yes, this has been discussed here. There is net buying pressure because more funds will need to buy to increase position in SP500 than will need to sell due to IDPH exiting midcap 600. But that's usually a transient thing.
Yes, but at end of day Thursday, the increased market cap will force mutual funds to add to their positions as the S&P 500 inclusion takes effect that day also...
So there will be some buying pressure
>>This merger is a done deal. <<
agreed. the institutional shares are the overwhealming majority, and will vote FOR
furthermore, whatever you want to call it (merger, acquisition, 50.1% technicalities aside) make no mistakes: Biogen is buying IDEC.
My only question is: how long before Biogen-Idec drops the "idec" and is just called "Biogen"
I'll guess 7 weeks.